{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T12:40:35Z","timestamp":1784292035475,"version":"3.55.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2018,11,26]],"date-time":"2018-11-26T00:00:00Z","timestamp":1543190400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1007\/s00262-018-2279-9","type":"journal-article","created":{"date-parts":[[2018,11,26]],"date-time":"2018-11-26T05:38:55Z","timestamp":1543210735000},"page":"297-303","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["Can benign lymphoid tissue changes in 18F-FDG PET\/CT predict response to immunotherapy in metastatic melanoma?"],"prefix":"10.1007","volume":"68","author":[{"given":"Christos","family":"Sachpekidis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lionel","family":"Larrib\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette","family":"Kopp-Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica C.","family":"Hassel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonia","family":"Dimitrakopoulou-Strauss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,11,26]]},"reference":[{"issue":"22 Pt 1","key":"2279_CR1","doi-asserted-by":"publisher","first-page":"6681","DOI":"10.1158\/1078-0432.CCR-07-0187","volume":"13","author":"SG Downey","year":"2007","unstructured":"Downey SG, Klapper JA, Smith FO et al (2007) Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin Cancer Res 13(22 Pt 1):6681\u20136688","journal-title":"Clin Cancer Res"},{"key":"2279_CR2","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi FS, O\u2019Day SJ, McDermott DF et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711\u2013723","journal-title":"N Engl J Med"},{"key":"2279_CR3","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1056\/NEJMoa1414428","volume":"372","author":"MA Postow","year":"2015","unstructured":"Postow MA, Chesney J, Pavlick AC et al (2015) Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 372:2006\u20132017","journal-title":"N Engl J Med"},{"key":"2279_CR4","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","volume":"373","author":"J Larkin","year":"2015","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R et al (2015) Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373:23\u201334","journal-title":"N Engl J Med"},{"issue":"21","key":"2279_CR5","doi-asserted-by":"publisher","first-page":"2691","DOI":"10.1200\/JCO.2012.41.6750","volume":"30","author":"JS Weber","year":"2012","unstructured":"Weber JS, K\u00e4hler KC, Hauschild A (2012) Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol 30(21):2691\u20132697","journal-title":"J Clin Oncol"},{"issue":"25","key":"2279_CR6","doi-asserted-by":"publisher","first-page":"6043","DOI":"10.1200\/JCO.2005.06.205","volume":"23","author":"P Attia","year":"2005","unstructured":"Attia P, Phan GQ, Maker AV et al (2005) Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol 23(25):6043\u20136053","journal-title":"J Clin Oncol"},{"issue":"5","key":"2279_CR7","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1053\/j.seminoncol.2010.09.003","volume":"37","author":"KC Kaehler","year":"2010","unstructured":"Kaehler KC, Piel S, Livingstone E, Schilling B, Hauschild A, Schadendorf D (2010) Update on immunologic therapy with anti-CTLA-4 antibodies in melanoma: identification of clinical and biological response patterns, immune-related adverse events, and their management. Semin Oncol 37(5):485\u2013498","journal-title":"Semin Oncol"},{"key":"2279_CR8","first-page":"1972","volume":"33","author":"R Kubota","year":"1992","unstructured":"Kubota R, Yamada S, Kubota K, Ishiwata K, Tamahashi N, Ido T (1992) Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med 33:1972\u20131980","journal-title":"J Nucl Med"},{"key":"2279_CR9","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1002\/jlb.59.5.639","volume":"59","author":"RL Gamelli","year":"1996","unstructured":"Gamelli RL, Liu H, He LK, Hofmann CA (1996) Augmentations of glucose uptake and glucose transporter-1 in macrophages following thermal injury and sepsis in mice. J Leukoc Biol 59:639\u2013647","journal-title":"J Leukoc Biol"},{"key":"2279_CR10","first-page":"1551","volume":"42","author":"T Mochizuki","year":"2001","unstructured":"Mochizuki T, Tsukamoto E, Kuge Y et al (2001) FDG uptake and glucose transporter subtype expressions in experimental tumor and inflammation models. J Nucl Med 42:1551\u20131555","journal-title":"J Nucl Med"},{"key":"2279_CR11","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1053\/snuc.2002.29278","volume":"32","author":"H Zhuang","year":"2002","unstructured":"Zhuang H, Alavi A (2002) 18-fluorodeoxyglucose positron emission tomographic imaging in the detection and monitoring of infection and inflammation. Semin Nucl Med 32:47\u201359","journal-title":"Semin Nucl Med"},{"key":"2279_CR12","first-page":"124","volume":"45","author":"JY Paik","year":"2004","unstructured":"Paik JY, Lee KH, Choe YS et al (2004) Augmented 18F-FDG uptake in activated monocytes occurs during the priming process and involves tyrosine kinases and protein kinase C. J Nucl Med 45:124\u2013128","journal-title":"J Nucl Med"},{"issue":"4","key":"2279_CR13","doi-asserted-by":"publisher","first-page":"647","DOI":"10.2967\/jnumed.112.112524","volume":"54","author":"F Jamar","year":"2013","unstructured":"Jamar F, Buscombe J, Chiti A et al (2013) EANM\/SNMMI guideline for 18F-FDG use in inflammation and infection. J Nucl Med 54(4):647\u2013658","journal-title":"J Nucl Med"},{"issue":"Suppl 1","key":"2279_CR14","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s00259-017-3691-7","volume":"44","author":"ANM Wong","year":"2017","unstructured":"Wong ANM, McArthur GA, Hofman MS, Hicks RJ (2017) The advantages and challenges of using FDG PET\/CT for response assessment in melanoma in the era of targeted agents and immunotherapy. Eur J Nucl Med Mol Imaging 44(Suppl 1):67\u201377","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"36","key":"2279_CR15","doi-asserted-by":"publisher","first-page":"6199","DOI":"10.1200\/JCO.2009.23.4799","volume":"27","author":"CM Balch","year":"2009","unstructured":"Balch CM, Gershenwald JE, Soong S-J et al (2009) Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 27(36):6199\u20136206","journal-title":"J Clin Oncol"},{"issue":"3","key":"2279_CR16","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1007\/s00259-017-3870-6","volume":"45","author":"H Anwar","year":"2018","unstructured":"Anwar H, Sachpekidis C, Winkler J et al (2018) Absolute number of new lesions in 18F-FDG PET\/CT is more predictive of clinical outcome than SUV changes in metastatic melanoma patients receiving ipilimumab. Eur J Nucl Med Mol Imaging 45(3):376\u2013383","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"8","key":"2279_CR17","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1007\/s00259-018-3972-9","volume":"45","author":"C Sachpekidis","year":"2018","unstructured":"Sachpekidis C, Anwar H, Winkler J et al (2018) The role of interim 18F-FDG PET\/CT in prediction of response to ipilimumab treatment in metastatic melanoma. Eur J Nucl Med Mol Imaging 45(8):1289\u20131296","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2279_CR18","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1007\/s00262-018-2183-3","volume":"67","author":"C Sachpekidis","year":"2018","unstructured":"Sachpekidis C, Anwar H, Winkler JK et al (2018) Longitudinal studies of the 18F-FDG kinetics after ipilimumab treatment in metastatic melanoma patients based on dynamic FDG PET\/CT. Cancer Immunol Immunother 67:1261\u20131270. \n                    https:\/\/doi.org\/10.1007\/s00262-018-2183-3\n                    \n                  . (Epub ahead of print)","journal-title":"Cancer Immunol Immunother"},{"key":"2279_CR19","first-page":"123","volume-title":"The metabolism of the human brain studied with positron emission tomography","author":"L Sokoloff","year":"1983","unstructured":"Sokoloff L, Smith CB (1983) Basic principles underlying radioisotopic methods for assay of biochemical processes in vivo. In: Greitz T, Ingvar DH, Wid\u00e9n L (eds) The metabolism of the human brain studied with positron emission tomography. Raven Press, New York, pp\u00a0123\u2013148"},{"key":"2279_CR20","first-page":"1432","volume":"32","author":"T Ohtake","year":"1991","unstructured":"Ohtake T, Kosaka N, Watanabe T et al (1991) Noninvasive method to obtain input function for measuring tissue glucose utilization of thoracic and abdominal organs. J Nucl Med 32:1432\u20131438","journal-title":"J Nucl Med"},{"key":"2279_CR21","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/0165-0270(93)90033-N","volume":"50","author":"H Miyazawa","year":"1993","unstructured":"Miyazawa H, Osmont A, Petit-Tabou\u00e9 MC et al (1993) Determination of 18F-fluoro-2-deoxy-d-glucose rate constants in the anesthetized baboon brain with dynamic positron tomography. J Neurosci Methods 50:263\u2013272","journal-title":"J Neurosci Methods"},{"key":"2279_CR22","first-page":"1818","volume":"38","author":"C Burger","year":"1997","unstructured":"Burger C, Buck A (1997) Requirements and implementation of a flexible kinetic modeling tool. J Nucl Med 38:1818\u20131823","journal-title":"J Nucl Med"},{"issue":"2","key":"2279_CR23","first-page":"127","volume":"5","author":"C Sachpekidis","year":"2015","unstructured":"Sachpekidis C, Thieke C, Askoxylakis V et al (2015) Combined use of (18)F-FDG and (18)F-FMISO in unresectable non-small cell lung cancer patients planned for radiotherapy: a dynamic PET\/CT study. Am J Nucl Med Mol Imaging 5(2):127\u2013142","journal-title":"Am J Nucl Med Mol Imaging"},{"key":"2279_CR24","first-page":"306","volume":"2","author":"A Dimitrakopoulou-Strauss","year":"2003","unstructured":"Dimitrakopoulou-Strauss A, Strauss LG, Mikolajczyk K, Burger C, Lehnert T, Bernd L, Ewerbeck V (2003) On the fractal nature of dynamic positron emission tomography (PET) studies. World J Nucl Med 2:306\u2013313","journal-title":"World J Nucl Med"},{"issue":"6","key":"2279_CR25","doi-asserted-by":"publisher","first-page":"W992","DOI":"10.2214\/AJR.10.6198","volume":"197","author":"Y Bronstein","year":"2011","unstructured":"Bronstein Y, Ng CS, Hwu P, Hwu WJ (2011) Radiologic manifestations of immune-related adverse events in patients with metastatic melanoma undergoing anti-CTLA-4 antibody therapy. Am J Roentgenol 197(6):W992\u2013W1000","journal-title":"Am J Roentgenol"},{"issue":"2","key":"2279_CR26","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1148\/rg.352140121","volume":"35","author":"JJ Kwak","year":"2015","unstructured":"Kwak JJ, Tirumani SH, Van den Abbeele AD, Koo PJ, Jacene HA (2015) Cancer immunotherapy: imaging assessment of novel treatment response patterns and immune-related adverse events. Radiographics 35(2):424\u2013437","journal-title":"Radiographics"},{"issue":"1","key":"2279_CR27","doi-asserted-by":"publisher","first-page":"4","DOI":"10.2214\/AJR.15.15480","volume":"207","author":"SA Howard","year":"2016","unstructured":"Howard SA, Krajewski KM, Jagannathan JP et al (2016) A new look at toxicity in the era of precision oncology: imaging findings, their relationship with tumor response, and effect on metastasectomy. Am J Roentgenol 207(1):4\u201314","journal-title":"Am J Roentgenol"},{"key":"2279_CR28","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/0026-2862(87)90011-2","volume":"33","author":"IC MacDonald","year":"1987","unstructured":"MacDonald IC, Ragan DM, Schmidt EE, Groom AC (1987) Kinetics of red blood cell passage through interendothelial slits into venous sinuses in rat spleen, analyzed by in vivo microscopy. Microvasc Res 33:118\u2013134","journal-title":"Microvasc Res"},{"issue":"2","key":"2279_CR29","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/S0300-9084(98)80024-2","volume":"80","author":"D Bratosin","year":"1998","unstructured":"Bratosin D, Mazurier J, Tissier JP et al (1998) Cellular and molecular mechanisms of senescent erythrocyte phagocytosis by macrophages. A review. Biochimie 80(2):173\u2013195. (Review)","journal-title":"Biochimie"},{"key":"2279_CR30","doi-asserted-by":"publisher","first-page":"274ra18","DOI":"10.1126\/scitranslmed.aaa0835","volume":"7","author":"Y Yin","year":"2015","unstructured":"Yin Y, Choi SC, Xu Z et al (2015) Normalization of CD41 T cell metabolism reverses lupus. Sci Transl Med 7:274ra18","journal-title":"Sci Transl Med"},{"issue":"3","key":"2279_CR31","doi-asserted-by":"publisher","first-page":"507","DOI":"10.2967\/jnumed.116.180729","volume":"58","author":"SS Ahn","year":"2017","unstructured":"Ahn SS, Hwang SH, Jung SM et al (2017) Evaluation of spleen glucose metabolism using 18F-FDG PET\/CT in patients with febrile autoimmune disease. J Nucl Med 58(3):507\u2013513","journal-title":"J Nucl Med"},{"issue":"Suppl 1","key":"2279_CR32","first-page":"S517","volume":"45","author":"C Sachpekidis","year":"2018","unstructured":"Sachpekidis C, Larribere L, Kopp-Schneider A, Haberkorn U, Hassel J, Dimitrakopoulou-Strauss A (2018) Benign lymphoid tissue changes as response to immunotherapy in metastatic melanoma patients: an 18F-FDG PET\/CT study. Eur J Nucl Med Mol Imaging 45 (Suppl 1): S517 (Abstract EP-0551)","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2279_CR33","doi-asserted-by":"publisher","first-page":"340","DOI":"10.2967\/jnumed.109.070946","volume":"51","author":"A Ribas","year":"2010","unstructured":"Ribas A, Benz MR, Allen-Auerbach MS et al (2010) Imaging of CTLA4 blockade-induced cell replication with (18)F-FLT PET in patients with advanced melanoma treated with tremelimumab. J Nucl Med 51:340\u2013346","journal-title":"J Nucl Med"},{"key":"2279_CR34","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s40425-016-0162-9","volume":"4","author":"KK Tsai","year":"2016","unstructured":"Tsai KK, Pampaloni MH, Hope C et al (2016) Increased FDG avidity in lymphoid tissue associated with response to combined immune checkpoint blockade. J Immunother Cancer 4:58","journal-title":"J Immunother Cancer"},{"issue":"1","key":"2279_CR35","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s13550-018-0435-z","volume":"8","author":"S Pektor","year":"2018","unstructured":"Pektor S, Hilscher L, Walzer KC et al (2018) In vivo imaging of the immune response upon systemic RNA cancer vaccination by FDG-PET. EJNMMI Res 8(1):80","journal-title":"EJNMMI Res"},{"key":"2279_CR36","doi-asserted-by":"publisher","first-page":"260","DOI":"10.2967\/jnmt.117.204933","volume":"46","author":"N Eshghi","year":"2018","unstructured":"Eshghi N, Garland LL, Nia E, Betancourt R, Krupinski E, Kuo PH (2018) 18F-FDG PET\/CT can predict development of thyroiditis due to immunotherapy for lung cancer. J Nucl Med Technol 46:260\u2013264","journal-title":"J Nucl Med Technol"},{"key":"2279_CR37","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1002\/ana.410060502","volume":"6","author":"ME Phelps","year":"1979","unstructured":"Phelps ME, Huang SC, Hoffman EJ et al (1979) Tomographic measurement of local cerebral glucose metabolic rate in humans with (F-18)2-fluoro-2-deoxy-d-glucose: validation of method. Ann Neurol 6:371\u2013388","journal-title":"Ann Neurol"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00262-018-2279-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-018-2279-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-018-2279-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,25]],"date-time":"2019-11-25T19:06:39Z","timestamp":1574708799000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00262-018-2279-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,26]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["2279"],"URL":"https:\/\/doi.org\/10.1007\/s00262-018-2279-9","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,26]]},"assertion":[{"value":"3 July 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 November 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Jessica C. Hassel received honoraria for talks and travel expenses from Bristol-Myers Squibb (BMS), Merck, Sharp & Dohm (MSD), Roche, Novartis, Pfizer and is a member of an advisory board for MSD and Amgen. The other authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The presented results are part of the study entitled \u201cQuantification of 18F-FDG kinetics with 4D PET-CT in patients with melanoma stage IV\u201d, which was approved by the Ethical Committee of the University of Heidelberg (Ethikvotum: S-107 \/2012\u2014Ethical Committee 1 of the University of Heidelberg) and the Federal Office for Radiation Protection (Bundesamt f\u00fcr Strahlenschutz; BfS: Z5- 22463 \/ 2 2012a-016). This study does not contain any studies with animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study. The patient presented in Fig.\u00a0 agreed to the publication of this figure.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}